140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations

K. Park; E. H. Tan; L. Zhang; V. Hirsh; K. O'Byrne; M. Boyer; J. Yang; T. Mok; M. Kim; L. Paz-Ares

doi:10.1016/S1556-0864(16)30250-7

140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations

K. Park
, E. H. Tan
, L. Zhang
, V. Hirsh
, K. O'Byrne
, M. Boyer
, J. Yang
, T. Mok
, M. Kim
, L. Paz-Ares

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Original language	English
Pages (from-to)	S117-S118
Journal	Journal of Thoracic Oncology
Volume	11
Issue number	4
DOIs	https://doi.org/10.1016/S1556-0864(16)30250-7
State	Published - Apr 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1556-0864(16)30250-7

Cite this

Park, K., Tan, E. H., Zhang, L., Hirsh, V., O'Byrne, K., Boyer, M., Yang, J., Mok, T., Kim, M., & Paz-Ares, L. (2016). 140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations. Journal of Thoracic Oncology, 11(4), S117-S118. https://doi.org/10.1016/S1556-0864(16)30250-7

@article{c0b0a15306884ff4b87403a0bda6f986,

title = "140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations",

author = "K. Park and Tan, \{E. H.\} and L. Zhang and V. Hirsh and K. O'Byrne and M. Boyer and J. Yang and T. Mok and M. Kim and L. Paz-Ares",

year = "2016",

month = apr,

doi = "10.1016/S1556-0864(16)30250-7",

language = "English",

volume = "11",

pages = "S117--S118",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier Inc.",

number = "4",

}

Park, K, Tan, EH, Zhang, L, Hirsh, V, O'Byrne, K, Boyer, M, Yang, J, Mok, T, Kim, M & Paz-Ares, L 2016, '140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations', Journal of Thoracic Oncology, vol. 11, no. 4, pp. S117-S118. https://doi.org/10.1016/S1556-0864(16)30250-7

140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations. / Park, K.; Tan, E. H.; Zhang, L. et al.
In: Journal of Thoracic Oncology, Vol. 11, No. 4, 04.2016, p. S117-S118.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - 140PD

T2 - LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations

AU - Park, K.

AU - Tan, E. H.

AU - Zhang, L.

AU - Hirsh, V.

AU - O'Byrne, K.

AU - Boyer, M.

AU - Yang, J.

AU - Mok, T.

AU - Kim, M.

AU - Paz-Ares, L.

PY - 2016/4

Y1 - 2016/4

UR - https://www.scopus.com/pages/publications/85037604373

U2 - 10.1016/S1556-0864(16)30250-7

DO - 10.1016/S1556-0864(16)30250-7

M3 - Article

AN - SCOPUS:85037604373

SN - 1556-0864

VL - 11

SP - S117-S118

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 4

ER -

Park K, Tan EH, Zhang L, Hirsh V, O'Byrne K, Boyer M et al. 140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations. Journal of Thoracic Oncology. 2016 Apr;11(4):S117-S118. doi: 10.1016/S1556-0864(16)30250-7

140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations

UN SDGs

Access to Document

Other files and links

Cite this